DOCSLIB.ORG

17Th Biennial Conference October 18-21, 2012 New York City, USA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
17Th Biennial Conference October 18-21, 2012 New York City, USA The "International Pharmaco-EEG Society, Association for Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields" (IPEG) is a non-profit organisation, established in 1980 and composed of scientists and researchers actively involved in electrophysiological brain research in preclinical and clinical pharmacology, neurotoxicology and related areas of interest. th 17 Biennial Conference October 18-21, 2012 New York City, USA Abstract Book TABLE OF CONTENTS KEYNOTES Keynote 1 – The science of pharmaco-EEG: a participant’s recollections ....................................... 22 Max Fink Keynote 2 – Rostral anterior cingulate function: a potential biomarker of antidepressant EEG-BASED PERSONALIZED MEDECINE treatment response? .................................................................................................................. 24 Diego A. Pizzagalli An introduction: EEG Subtypes and Endophenotypes Keynote 3 – Contribution of QEEG and subtyping to outcome prediction ...................................... 25 QEEG subtyping and treatment optimization and outcome .......................................................... 10 Leslie S. Prichep Leslie S. Prichep Keynote 4 – Why have sleep deprivation pro-manic and psychostimulants anti-manic effects? A review and integration of EEG-based predictors for treatment outcome in ADHD and The wakefulness regulation model of affective disorders ........................................................ 26 depression ...................................................................................................................................... 11 Ulrich Hegerl Martijn Arns Keynote 5 – Relationship between ADHD and sleep problems: A new etiology perspective ......... 27 ‘EEG Cordance’ and the ATR (Antidepressant Treatment Response) Martijn Arns Neurophysiologic predictors of treatment response in major depression ..................................... 12 Andrew F. Leuchter SYMPOSIA Prefrontal EEG Cordance as a predictor of response to antidepressive treatment in patients Symposium 1 – Translational biomarkers in pharmaco-EEG – from bench to bed and back with MDD and Bipolar depression ................................................................................................ 13 Martin Brunovsky Quantitative EEG in glutamatergic and serotonergic pharmacological models of schizophrenia – a translational approach ...................................................................................... 31 ERP approaches to Personalized Medicine and EEG Vigilance Tomáš Páleníček Resting EEG and evoked potential predictors of clinical response to antidepressants ................. 14 Translational validity of EEG oscillations in schizophrenia ......................................................... 32 Gerard Bruder Abdellah Ahnaou Can vigilance regulation be used to predict clinical response to antidepressants? ....................... 15 Intravenous ketamine for treatment-resistant unipolar depression: comparison of Ulrich Hegerl pharmaco-EEG changes in responders and non-responders ......................................................... 33 Martin Brunovsky EEG based Personalized Medicine: The Industry perspective A functional data analysis framework for pharmaco-EEG modeling and inference .................... 34 Biomarker Discovery – Integrative Neuroscience and EEG Biomarkers ..................................... 16 Junshui Ma Evian Gordon and Chris Spooner Symposium 2 – Genetic influences on the pharmaco-EEG in psychiatric diseases and its Pharmacologic treatment of major depressive disorder guided by QEEG .................................... 17 potential for new pharmacological treatments Daniel A. Hoffman (presented by Mark Schiller) Genetic influences on the resting EEG, alcoholism and anxiety – convergent findings .............. 35 Mary-Anne Enoch A mouse model of 15q13.3 microdeletion syndrome display pre-attentive processing deficits and EEG phenotypes seen in schizophrenia ..................................................................... 36 Dr. E. ROY JOHN MEMORIAL LECTURE Jesper F. Bastlund New methods for studying localized function and distributed whole brain connectivity Interindividual differences in the acute effects of cannabis on performance monitoring and patterns using EEG tomographies ................................................................................................. 19 inhibitory control ........................................................................................................................... 37 Roberto D. Pascual-Marqui Desirée Spronk Modulation of different EEG parameters and depressive impact mood influencing genes of COMT and BDNF ......................................................................................................................... 38 Niels Veth 3 17th Biennial Conference IPEG 2012 in New York 4 Symposium 3 – EEG-based biomarkers in diagnosis and prediction of Session 2 psychopharmacological treatment in neuropsychiatric disorders Effects of the novel anxiolytic drug ABIO 08/01 on sleep and awakening quality in EEG-vigilance regulation in major depression – from theory to treatment prediction ................. 39 generalized anxiety disorder - polysomnographic and psychometric studies ............................... 53 Sebastian Olbrich Sergio Rosales-Rodríguez Response prediction to antidepressants using alpha power and asymmetry and anterior Single-blind, randomized, increasing-dose study of the novel anxiolytic drug ABIO 08/01 cingulate cortex theta activity ....................................................................................................... 40 in generalized anxiety disorder - clinical and qEEG findings ....................................................... 54 Natalia Jaworska Bernd Saletu Cordance as a biomarker in sleep-EEG for treatment response in depression – a naturalistic Towards a normative database for sleep macro- and microstructure ............................................ 55 study after antidepressant medication ........................................................................................... 41 Peter Anderer Marcel Pawlowski Music therapy added to standard care modulates fronto-temporal activity in the rest-EEG ADHD – Predicting response to stimulant medication on the basis of event-related in depressed clients with comorbid anxiety .................................................................................. 56 potentials ....................................................................................................................................... 42 Jörg Fachner Geir Ogrim qEEG features and medicinal response in epilepsy ...................................................................... 43 Session 3 Hamlin Emory EEG vs. Psychometry .................................................................................................................... 57 John Marks – Pharmaco-EEG and pharmaco-sleep in drug-discovery and development Symposium 4 EEG and ERP changes following oral intake of specified oregano extracts: similarities and The role of EEG and PSG in decision-making in early drug development .................................. 44 differences to antidepressant markers ........................................................................................... 58 Frederick J. Wilson Peter H. Boeijinga Lost in translation .......................................................................................................................... 45 Nicotine-related alterations of p50-indexed sensory gating in cannabis users ............................. 59 Gé S.F. Ruigt Derek J. Fisher Visual scoring and computerized data processing are complementary tools – a pharmaco- sleep study investigating the effects of a new antidepressant compared to imipramine ............... 46 Session 4 Marc Jobert Functional connectivity in schizophrenic patients who were treated with aripiprazole................ 60 Sleep architecture as a translatable biomarker of central pharmacology in the development Masafumi Yoshimura of PF-04457845, an inhibitor of fatty acid amide hydrolase ......................................................... 47 Electroencephalographic patterns of the internal connectivity networks of the brain as Rachel Gurrell revealed by simultaneous EEG/fMRI measurements .................................................................... 61 Tamer Demiralp The qEEG characteristics of ADHD children, responders and non-responders to long-term ORAL PRESENTATIONS treatment with Atomoxetine .......................................................................................................... 62 Session 1 Giuseppe A. Chiarenza ERPs to emotionally loaded words as an assessment tool ............................................................ 50 Einat Ofek The effect of attenuating noradrenergic neurotransmission by clonidine on brain activity measures of visuospatial attention ................................................................................................. 51 H.N. Alexander Logemann Electrophysiological and fMRI assessments of perceptual function for use in clinical trials ....... 52 Pamela D. Butler 5 17th Biennial Conference IPEG 2012 in New York 6 POSTER PRESENTATIONS [1] Brain source connectivity for visceral pain and pharmaco-EEG ............................................. 64 [13] Quantitative electrophysiology in hyperthyroidism: Polysomnographic, EEG/ERP Dina Lelic, Søren S. Olesen,
Load more

Recommended publications
  • HINDEMITH VAN DER ROOST Clarinet Concertos Eddy Vanoosthuyse, Clarinet Central Aichi Symphony Orchestra Sergio Rosales, Conductor
    HINDEMITH VAN DER ROOST Clarinet Concertos Eddy Vanoosthuyse, Clarinet Central Aichi Symphony Orchestra Sergio Rosales, Conductor 1 Paul Hindemith (1895−1963): Clarinet Concerto Born in Frankfurt in 1895, the son of a house-painter, Paul Hindemith studied the violin privately with teachers from the Hoch Conservatory before being admitted to that institution with a free place at the age of thirteen. By 1915 he was playing second violin in his teacher Adolf Rebner’s quartet and had a place in the opera orchestra, of which he became leader in the same year. His father was killed in the war and Hindemith himself spent some time from 1917 as a member of a regimental band, returning after the war to the Rebner Quartet and the Frankfurt Opera Orchestra. At the same time he was making his name as a composer of particular originality, striving to bring about a revolution in concert-going with his concept of Gebrauchsmusik (functional or utility music), and devoting much of his energy to the promotion of new music, in particular at the Donaueschingen Festival. Having changed from violin to viola, he formed the Amar-Hindemith Quartet in 1921, an ensemble that won considerable distinction for its performances of new music. In 1927 Hindemith was appointed professor of composition at the Berlin Musikhochschule, two years later disbanding the quartet – to which he could no longer give time – and instead performing in a string trio with Josef Wolfsthal, (replaced on his death by Szymon Goldberg) and the cellist Emanuel Feuermann. He was also enjoying a career as a viola soloist.
    [Show full text]
  • Nootropic Concepts
    Nootropic concepts intelligent ingredient for gut health Nootropics definition Nootropic is a substance that enhances cognition and memory and facilitates learning. Nootropics work in many ways to produce a range of benefits across memory, focus, attention, motivation, relaxation, mood, alertness, stress resistance. Bluenesse® Bluenesse® – an innovative, exclusive lemon balm extract, Melissa officinalis (L.) – supports your mental health. It has an immediate effect on focus, concentration, and memory. Furthermore, it supports a calm and good mood and helps to balance the stress hormone cortisol. Bluenesse® - Nootropics concepts Nootropic benefits of Bluenesse® and the underlying mode of action: Bluenesse® - Nootropics concepts – detailed information: Several, double blind, randomized, placebo-controlled, crossover human study results have shown that Bluenesse® supports nootropic effects on demand. Below, the investigated parameter and mode of action is explained per each nootropic application. Vital Solutions GmbH, Hausingerstrasse 6, D-40764 Langenfeld, +49 (0) 2173 109 82 02 [email protected] www.vitalsolutions.biz . Nootropic concepts Cognitive performance support and enhancing learning & memory: Bluenesse® significantly improves cognitive performance, particularly alertness, working memory and mathematic processing by improving the efficiency of neuronal communication. It activates Muscarinic receptors, which are responsible for the efficient flow of information between neurological cells, so-called “oscillation”, leading to
    [Show full text]
  • Nootropics for Healthy Individuals
    Trinity College Trinity College Digital Repository Trinity Publications (Newspapers, Yearbooks, The First-Year Papers (2010 - present) Catalogs, etc.) 2015 Nootropics for Healthy Individuals Jin Pyo Jeon Trinity College, Hartford Connecticut, [email protected] Follow this and additional works at: https://digitalrepository.trincoll.edu/fypapers Part of the Chemicals and Drugs Commons Recommended Citation Jeon, Jin Pyo, "Nootropics for Healthy Individuals". The First-Year Papers (2010 - present) (2015). Trinity College Digital Repository, Hartford, CT. https://digitalrepository.trincoll.edu/fypapers/61 Nootropics for Healthy Individuals Jin Pyo Jeon With recent advances in fields like biotechnology and genetic engineering, the concern for a just and equal distribution of human enhancement technologies undoubtedly became one of the most significant ethical dilemmas of the 21st century. And with the sudden rise of cognitive enhancement drug (otherwise called as nootropics) use in society, the need for developing policies to address these dilemmas have now become an urgent issue that the scientific and political community must confront. Once only used by the few with special needs or neurological disorders, nootropics are now being utilized by a significant part of the population for cognitive enhancement, inciting a debate of the regulation and legalization of nootropics. Nonetheless, given the currently known benefits and risks of nootropics, the mechanisms through which nootropics function, and the ineffectiveness of policy restrictions, it would be more pragmatic to inform and allow for the non-prescription uses for some nootropics rather than to restrict its use. Benefits, Risks, and Viability of the Use of Nootropics Among many other nootropics, two drugs have become the de facto nootropics for many healthy individuals: modafinil (commercially known as Provigil) and methylphenidate (commercially known as Ritalin).
    [Show full text]
  • Neuroenhancement in Healthy Adults, Part I: Pharmaceutical
    l Rese ca arc ni h li & C f B o i o l e Journal of a t h n Fond et al., J Clinic Res Bioeth 2015, 6:2 r i c u s o J DOI: 10.4172/2155-9627.1000213 ISSN: 2155-9627 Clinical Research & Bioethics Review Article Open Access Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review Fond G1,2*, Micoulaud-Franchi JA3, Macgregor A2, Richieri R3,4, Miot S5,6, Lopez R2, Abbar M7, Lancon C3 and Repantis D8 1Université Paris Est-Créteil, Psychiatry and Addiction Pole University Hospitals Henri Mondor, Inserm U955, Eq 15 Psychiatric Genetics, DHU Pe-psy, FondaMental Foundation, Scientific Cooperation Foundation Mental Health, National Network of Schizophrenia Expert Centers, F-94000, France 2Inserm 1061, University Psychiatry Service, University of Montpellier 1, CHU Montpellier F-34000, France 3POLE Academic Psychiatry, CHU Sainte-Marguerite, F-13274 Marseille, Cedex 09, France 4 Public Health Laboratory, Faculty of Medicine, EA 3279, F-13385 Marseille, Cedex 05, France 5Inserm U1061, Idiopathic Hypersomnia Narcolepsy National Reference Centre, Unit of sleep disorders, University of Montpellier 1, CHU Montpellier F-34000, Paris, France 6Inserm U952, CNRS UMR 7224, Pierre and Marie Curie University, F-75000, Paris, France 7CHU Carémeau, University of Nîmes, Nîmes, F-31000, France 8Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany *Corresponding author: Dr. Guillaume Fond, Pole de Psychiatrie, Hôpital A. Chenevier, 40 rue de Mesly, Créteil F-94010, France, Tel: (33)178682372; Fax: (33)178682381; E-mail: [email protected] Received date: January 06, 2015, Accepted date: February 23, 2015, Published date: February 28, 2015 Copyright: © 2015 Fond G, et al.
    [Show full text]
  • Nootropic and Anti-Alzheimer's Actions of Medicinal Plants
    Molecular Neurobiology (2019) 56:4925–4944 https://doi.org/10.1007/s12035-018-1420-2 Nootropic and Anti-Alzheimer’s Actions of Medicinal Plants: Molecular Insight into Therapeutic Potential to Alleviate Alzheimer’s Neuropathology Md. Sahab Uddin1 & Abdullah Al Mamun1 & Md. Tanvir Kabir 2 & Md. Jakaria3 & Bijo Mathew4 & George E. Barreto5,6 & Ghulam Md Ashraf7 Received: 5 September 2018 /Accepted: 29 October 2018 /Published online: 9 November 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Medicinal plants are the backbone of modern medicine. In recent times, there is a great urge to discover nootropic medicinal plants to reverse cognitive dysfunction owing to their less adverse effects. Alzheimer’s disease (AD) is an age-related neurode- generative disorder characterized by the inevitable loss of cognitive function, memory and language impairment, and behavioral disturbances, which turn into gradually more severe. Alzheimer’s has no current cure, but symptomatic treatments are available and research continues. The number of patients suffering from AD continues to rise and today, there is a worldwide effort under study to find better ways to alleviate Alzheimer’s pathogenesis. In this review, the nootropic and anti-Alzheimer’spotentialsof6 medicinal plants (i.e., Centella asiatica, Clitoria ternatea, Crocus sativus, Terminalia chebula, Withania somnifera,and Asparagus racemosus) were explored through literature review. This appraisal focused on available information about neuro- protective and anti-Alzheimer’s use of these plants and their respective bioactive compounds/metabolites and associated effects in animal models and consequences of its use in human as well as proposed molecular mechanisms. This review progresses our existing knowledge to reveal the promising linkage of traditional medicine to halt AD pathogenesis.
    [Show full text]
  • Drugs Influencing Cognitive Function
    Indian J Physiol Phannacol 1994; 38(4) : 241-251 RE\llEW ARTICLE DRUGS INFLUENCING COGNITIVE FUNCTION ALICE KURUYILLA* AND YASUNDARA DEYI Department ofPharmacology. Christian Medical College. Vellore - 632 002 DRUGS INFLUENCING COGNITIVE FUNCTION cerebrovascular disorders with dementias and reversible dementias. Drugs can inOuence cognitive function in several different ways. The cognitrve enhancers or nootropics Primary degenerative disorders include the have become a major issue in drug development during subgroups senile dementia of the Alzheimer's type the last decade. Nootropics arc defined as drugs that (SDAT), Alzheimer's disease, Picks disease and generally increase neuron metabolic activity, improve Huntington's chorea (4). Alzheimer's disease usually cognitive and ,'igilance level and are said to have occurs in individuals past 70 years old and appears to antidemcntia effect (I). These drugs are essential for be in part genetically determin'd (5). the treatment of geriatric disorders like Alzheimer's which have become one of the major problems socially Pathophysiology oj Alzheimer's disease : and medically. Considerable evidence has been gathered Extensive research in the recent years has made major in the last decade to support the observation that advances in understanding the pathogenesis of children with epilepsy have morc learning difficulties Alzheimer's disease (6). The hallmark lesions of than age matched controls (2, 3). Anti-epileptic drugs Alzheimer's disease are neuritic plaques and are useful in controlling the frequency and duration of neurofibrillary tangles. Two amyloid proteins seizures. These drugs can also be the source of side accumulate in Alzheimer's disease, these arc beta effects including cognitive impairment.
    [Show full text]
  • For Peer Review Only
    BMJ Open BMJ Open: first published as 10.1136/bmjopen-2016-012177 on 30 November 2016. Downloaded from Commonly prescribed drugs associated with cognition: a cross-sectional study in UK Biobank ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2016-012177 Article Type: Research Date Submitted by the Author: 06-Apr-2016 Complete List of Authors: Nevado-Holgado, Alejo; University of Oxford, Psychiatry Kim, Chi-Hun; University of Oxford, Psychiatry Winchester, Laura; University of Oxford, Psychiatry Gallacher, John; University of Oxford, Psychiatry Lovestone, Simon; University of Oxford, Psychiatry <b>Primary Subject Public health Heading</b>: Secondary Subject Heading: Mental health, Pharmacology and therapeutics, Neurology Keywords: PUBLIC HEALTH, MENTAL HEALTH, Cognition, UK biobank http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. For peer review only − http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 16 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2016-012177 on 30 November 2016. Downloaded from 1 2 3 Commonly prescribed drugs associate with cognition: a cross-sectional study 4 in UK Biobank 5 6 7 8 Authors 9 10 Alejo J Nevado-Holgado*, Chi-Hun Kim*, Laura Winchester, John Gallacher, Simon Lovestone 11 12 13 14 15 Address For peer review only 16 17 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK 18 19 20 21 22 23 Authors’ names and positions 24 25 Alejo J Nevado-Holgado*: Postdoctoral researcher 26 27 Chi-Hun Kim*: Postdoctoral researcher 28 29 Laura Winchester: Postdoctoral researcher 30 31 John Gallacher: Professor 32 33 Simon Lovestone: Professor 34 http://bmjopen.bmj.com/ 35 *These authors contributed equally to this work.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0155676 A1 Burnett Et Al
    US 20070 155676A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0155676 A1 Burnett et al. (43) Pub. Date: Jul. 5, 2007 (54) SUBSTITUTED AZETIONONE (60) Provisional application No. 60/452,725, filed on Mar. COMPOUNDS, PROCESSES FOR 7, 2003. PREPARING THE SAME, FORMULATIONS AND USES THEREOF Publication Classification (75) Inventors: Duane A. Burnett, Bernardsville, NJ (51) Int. Cl. (US); John W. Clader, Cranford, NJ A61K 3 1/7052 (2006.01) (US) A6II 3 L/506 (2006.01) A61K 31/4709 (2006.01) Correspondence Address: A61K 31/4025 (2006.01) SCHERING-PLOUGH CORPORATION A61K 31/4439 (2006.01) PATENT DEPARTMENT (K-6-1, 1990) A 6LX 3L/397 (2006.01) 2000 GALLOPNG HILL ROAD C07D 405/14 (2006.01) KENILWORTH, NJ 07033-0530 (US) C07D 405/02 (2006.01) (52) U.S. Cl. ..................... 514/23: 514/210.02:536/17.3; (73) Assignee: Schering Corporation, Kenilworth, NJ 54O72OO (21) Appl. No.: 11/708,449 (57) ABSTRACT Filed: Feb. 20, 2007 The present invention provides substituted azetidinone com (22) pounds, formulations and processes for preparing the same Related U.S. Application Data which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, (62) Division of application No. 10/792.346, filed on Mar. stroke, demyelination and lowering plasma levels of sterols 3, 2004, now Pat. No. 7,208,486. and/or stanols in a subject. US 2007/O 155676 A1 Jul. 5, 2007 SUBSTITUTED AZETIDINONE COMPOUNDS, 0006 U.S. Pat. Nos. 5,846,966 and 5,661,145, respec PROCESSES FOR PREPARING THE SAME, tively, disclose treatments for inhibiting atherosclerosis and FORMULATIONS AND USES THEREOF reducing plasma cholesterol levels using Such hydroxy Substituted aZetidinone compounds or Substituted B-lactam CROSS-REFERENCE TO RELATED compounds in combination with HMG CoA reductase APPLICATION inhibitor compounds, which act by blocking hydroxymeth 0001.
    [Show full text]
  • The Use and Impact of Cognitive Enhancers Among University Students: a Systematic Review
    brain sciences Systematic Review The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review Safia Sharif 1 , Amira Guirguis 1,2,* , Suzanne Fergus 1,* and Fabrizio Schifano 1 1 Psychopharmacology, Substance Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK; [email protected] (S.S.); [email protected] (F.S.) 2 Institute of Life Sciences 2, Swansea University, Swansea SA2 8PP, Wales, UK * Correspondence: [email protected] (A.G.); [email protected] (S.F.) Abstract: Introduction: Cognitive enhancers (CEs), also known as “smart drugs”, “study aids” or “nootropics” are a cause of concern. Recent research studies investigated the use of CEs being taken as study aids by university students. This manuscript provides an overview of popular CEs, focusing on a range of drugs/substances (e.g., prescription CEs including amphetamine salt mixtures, methylphenidate, modafinil and piracetam; and non-prescription CEs including caffeine, cobalamin (vitamin B12), guarana, pyridoxine (vitamin B6) and vinpocetine) that have emerged as being misused. The diverted non-prescription use of these molecules and the related potential for dependence and/or addiction is being reported. It has been demonstrated that healthy students (i.e., those without any diagnosed mental disorders) are increasingly using drugs such as methylphenidate, a mixture of dextroamphetamine/amphetamine, and modafinil, for the purpose of increasing their alertness, concentration or memory. Aim: To investigate the level of knowledge, perception and impact of the use of a range of CEs within Higher Education Institutions.
    [Show full text]
  • Practitioner Dietary Supplement Reference Guide
    Practitioner Dietary Supplement Reference Guide dotFIT™ ThermAccelTM Goal To accelerate or continue desired weight loss, especially when diet and exercise may be maximized based on acceptable lifestyle parameters, by supplying effectively timed doses of bioactive ingredients that have separately demonstrated favorable effects through unique targets on human body fat metabolism leading to enhanced body fat/weight loss when compared to a non-supplemented state. Daily simultaneous ingestion of these combined actives may contribute additive effects since the individual mechanisms of action related to fat oxidation, energy expenditure and appetite are distinctly unique. The formula’s primary goal is to increase total daily energy expenditure/calorie burn (TDEE) by increasing resting energy expenditure (REE) and overall metabolism including daily activities. ThermAccel’s (TA) natural thermogenic blend is uniquely formulated to deliver a “better stimulant effect” when compared to currently available popular energy formulas that often lead to "burnout" and related stress, including "end of day fatigue." ThermAccel is designed to produce balanced and enhanced energy levels that may also help users increase voluntary daily activities. Through TA’s thermogenic effect (boosting metabolism by wasting calories as heat), favorable fat oxidation properties and smoother daily energy boost, users may be able to avoid or overcome natural plateaus during weight reduction without having to continually "add more work.” TA’s secondary endpoints are to increase fat oxidation/burning (energy/nutrient partitioning) and decrease appetite beyond TA’s caffeine stimulant blend’s normal effects on these targets, by incorporating two other groups of natural ingredients, Caralluma fimbriata and Sinetrol (the polyphenols naringin and neohesperidin), which work through respectively different body fat regulation pathways than the thermogenic blend.
    [Show full text]
  • Cognitive Enhancers
    Cognitive enhancers Memory enhancers are often referred to as "smart drugs", "study drugs",[1] "smart nutrients", "cognitive enhancers", "brain enhancers" or in the scientific literature as nootropics.[2] They are drugs that are purported to improve human cognitive abilities.[3][4] The term covers a broad range of substances including drugs, nutrients and herbs with purported cognitive enhancing effects. The word nootropic was coined in 1964 by Dr. Corneliu E. Giurgea, derived from the Greek words noos, or "mind," and tropein meaning "to bend/turn". Typically, nootropics are thought to work by altering the availability of the brain's supply of neurochemicals (neurotransmitters, enzymes, and hormones), by improving the brain's oxygen supply, or by stimulating nerve growth. However the efficacy of nootropic substances in most cases has not been conclusively determined. This is complicated by the difficulty of defining and quantifying cognition and intelligence. Contents 1 Availability 2 Examples 2.1 Stimulants 2.2 Replenishing and increasing neurotransmitters 2.2.1 Cholinergics 2.2.1.1 Piracetam 2.2.1.2 Aniracetam 2.2.1.3 Other cholinergics 2.2.1.4 Acetylcholinesterase inhibitors 2.2.2 Dopaminergics 2.2.3 Serotonergics 2.3 Anti-depression, adaptogenic (antistress), and mood stabilization 2.4 Brain function and improved oxygen supply 2.5 Purported memory enhancement and learning improvement 2.6 Nerve growth stimulation and brain cell protection 2.7 Recreational drugs with purported nootropic effects 2.8 Dietary nootropics 2.9 Other nootropics 2.9.1 Contentious or possibly unsafe nootropics 3 See also 3.1 Brain and neurology 3.2 Thought and thinking (what nootropics are used for) 3.3 Health 4 References 5 External links Availability Currently there are several drugs on the market that improve memory, concentration, planning and reduce impulsive behavior.
    [Show full text]
  • CV Prof. Reiter RJ
    CURRICULUM VITAE Updated December 2015 NAME : Russel J. Reiter CURRENT AFFILIATION : Department of Cellular and Structural Biology, University of Texas Health Science Center San Antonio, Texas 78229-3900 USA PHONE : (210) 567-3859 FAX : (210) 567-6948 ELECTRONIC MAIL : [email protected] MILITARY SERVICE : Captain, Medical Service Corps (Jan, l964 to Jan, l966) ACADEMIC TRAINING : St. John's University, Collegeville, MN, 1954-1959 Bowman Gray School of Medicine at Wake Forest College, Winston-Salem, NC, 1960- 1964 DEGREES : B.A., 1959, Biology, St. John's University M.S., 1961, Anatomy, Bowman Gray School of Medicine Ph.D., 1964, Anatomy (Endocrinology), Bowman Gray School of Medicine Honorary M.D. (Doctor Honoris Causa), 1990, Medical Academy of Lodz, Lodz, Poland Honorary M.D. (Doctor Honoris Causa), 1992, La Laguna University, La Laguna, Spain Honorary M.D. (Doctor Honoris Causa), 1999, University of Granada, Granada, Spain Honorary D.Sc. (Doctor Honoris Causa), 2006, University of Extremadura, Badajoz, Spain POSITIONS HELD AND DATES : University of North Dakota, Grand Forks, ND, NSF Cooperative Graduate Fellowship (Summer) l960. Bowman Gray School of Medicine, Winston-Salem, NC, Graduate Teaching Assistant, l960-l96l. Bowman Gray School of Medicine, Winston-Salem, NC, Radiation Biology Traineeship (NIH), Radiology, l96l-l963. U.S. Army Edgewood Arsenal, Edgewood Arsenal, MD, Captain, Medical Service Corps & Research Biologist, l964-l966. U.S. Army Edgewood Arsenal, Experimental Endocrinologist, Research Laboratories, Edgewood Arsenal, MD, Jan. l966 - Aug. l966. University of Rochester, Rochester, NY, Assistant Professor of Anatomy, Department of Anatomy, l966-l969. University of Rochester, Rochester, NY, Associate Professor of Anatomy, Department of Anatomy, l969-l97l.
    [Show full text]